Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of EPA and DHA as Tailored Therapy for People Living With Obesity and High-risk for Type 2 Diabetes (END-T2D): a Randomized Controlled Trial

NCT07575438 is registered in ClinicalTrials.gov with May Faraj, PDt, PhD as lead sponsor.

NCT NCT07575438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07575438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of EPA and DHA as Tailored Therapy for People Living With Obesity and High-risk for Type 2 Diabetes (END-T2D): a Randomized Controlled Trial
Lead sponsor
May Faraj, PDt, PhD
Phase
Phase 2
Overall status
Recruiting
Start date
October 5, 2026
Completion date
December 31, 2029
Enrollment
84 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity & overweight, obesity and diabetes mellitus, type 2, prediabetes (insulin resistance, impaired glucose tolerance), prediabetes / type 2 diabetes, type 2 diabetes